Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Celgene Corp (NASDAQ:CELG)

104.50
Delayed Data
As of Nov 21
 +1.35 / +1.31%
Today’s Change
94.55
Today|||52-Week Range
147.17
-9.72%
Year-to-Date
Agios Posts New Data on Glioma Candidate from Dose Expansion
Nov 20 / Zacks.com - Paid Partner Content
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3
Nov 17 / Zacks.com - Paid Partner Content
The Market Tells a Tale of Two Gaps
Nov 20 / TheStreet.com - Paid Partner Content
Stanley Druckenmiller Starts 3 Positions in 3rd Quarter
Nov 15 / GuruFocus News - Paid Partner Content
Cancer Space Update: Label Expansion for Three Major Drugs
Nov 17 / Zacks.com - Paid Partner Content
Celgene sales target cuts signal wider biotech blues
Oct 26 / FT.com - Paid Partner Content
Celgene CAR-T Therapy Gets Breakthrough Therapy Designation
Nov 17 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close103.15
Today’s open103.69
Day’s range103.50 - 105.98
Volume7,092,052
Average volume (3 months)5,864,669
Market cap$81.2B
Dividend yield--
Data as of 4:15pm ET, 11/21/2017

Growth & Valuation

Earnings growth (last year)+28.35%
Earnings growth (this year)+23.54%
Earnings growth (next 5 years)+20.25%
Revenue growth (last year)+22.70%
P/E ratio24.5
Price/Sales8.51
Price/Book12.17

Competitors

 Today’s
change
Today’s
% change
BMYBristol-Myers Squibb+0.44+0.72%
GSKGlaxoSmithKline-0.31-0.88%
ABBVAbbVie+1.08+1.15%
SNYSanofi+0.47+1.06%
Data as of 4:02pm ET, 11/21/2017

Financials

Next reporting dateJanuary 25, 2018
EPS forecast (this quarter)$1.92
Annual revenue (last year)$10.9B
Annual profit (last year)$2.0B
Net profit margin18.30%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Mark J. Alles
President &
Chief Operating Officer
Scott Andrew Smith
Corporate headquarters
Summit, New Jersey

Forecasts